Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination
View ORCID ProfileM. Eugenia Toledo-Romani, M. Garcia-Carmenate, View ORCID ProfileC. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, View ORCID ProfileM. Rodríguez Ortega, View ORCID ProfileN. L. Herrera Marrero, View ORCID ProfileE. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, View ORCID ProfileY. Climent Ruiz, Y. Valdes-Balbin, View ORCID ProfileD. Garcia-Rivera, View ORCID ProfileV. Verez Bencomo, SOBERANA Phase 3 team
doi: https://doi.org/10.1101/2021.10.31.21265703
M. Eugenia Toledo-Romani
2“Pedro Kouri”Tropical Medicine Institute, Havana
M. Garcia-Carmenate
3Havana Hygiene and Epidemiological Center
C. Valenzuela Silva
4Institute of Cybernetics, Mathematics and Physics, Havana
W. Baldoquin-Rodriguez
2“Pedro Kouri”Tropical Medicine Institute, Havana
M. Martínez Pérez
1Finlay Vaccine Institute, Havana
M. C. Rodríguez Gonzalez
1Finlay Vaccine Institute, Havana
B. Paredes Moreno
1Finlay Vaccine Institute, Havana
I. C. Mendoza Hernández
5Center for Coordination of Clinical Trial, Havana
R. González-Mujica Romero
1Finlay Vaccine Institute, Havana
O. Samón Tabio
6Technological Havana University “José Antonio Echevarría”
P. M. Velazco Villares
7UCT Geocuba Research and consultation, Havana
J. P. Bacallao Castillo
7UCT Geocuba Research and consultation, Havana
E. Licea Martín
1Finlay Vaccine Institute, Havana
M. Rodríguez Ortega
2“Pedro Kouri”Tropical Medicine Institute, Havana
N. L. Herrera Marrero
2“Pedro Kouri”Tropical Medicine Institute, Havana
E. Caballero Gonzalez
1Finlay Vaccine Institute, Havana
L. I. Egües Torres
3Havana Hygiene and Epidemiological Center
R. Duarte González
3Havana Hygiene and Epidemiological Center
S. García Blanco
3Havana Hygiene and Epidemiological Center
S. Pérez Cabrera
3Havana Hygiene and Epidemiological Center
S. Huete Ferreira
3Havana Hygiene and Epidemiological Center
K. Idalmis Cisnero
3Havana Hygiene and Epidemiological Center
O. Fonte Galindo
3Havana Hygiene and Epidemiological Center
D. Meliá Pérez
3Havana Hygiene and Epidemiological Center
I. Rojas Remedios
3Havana Hygiene and Epidemiological Center
S. Fernandez Castillo
1Finlay Vaccine Institute, Havana
Y. Climent Ruiz
1Finlay Vaccine Institute, Havana
Y. Valdes-Balbin
1Finlay Vaccine Institute, Havana
D. Garcia-Rivera
1Finlay Vaccine Institute, Havana
V. Verez Bencomo
1Finlay Vaccine Institute, Havana
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted November 01, 2021.
Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three doses combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (671)
- Anesthesia (181)
- Cardiovascular Medicine (2661)
- Dermatology (224)
- Emergency Medicine (402)
- Epidemiology (12264)
- Forensic Medicine (10)
- Gastroenterology (765)
- Genetic and Genomic Medicine (4122)
- Geriatric Medicine (387)
- Health Economics (681)
- Health Informatics (2670)
- Health Policy (1008)
- Hematology (364)
- HIV/AIDS (855)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (442)
- Neurology (3912)
- Nursing (210)
- Nutrition (582)
- Oncology (2048)
- Ophthalmology (587)
- Orthopedics (242)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1116)
- Primary Care Research (455)
- Public and Global Health (6551)
- Radiology and Imaging (1410)
- Respiratory Medicine (872)
- Rheumatology (412)
- Sports Medicine (344)
- Surgery (452)
- Toxicology (54)
- Transplantation (186)
- Urology (167)